Just need them to execute and watch cash burn rate. Once Vyleesi is approved that could bring in revenues of up to 70M per year just from North America royalties alone.

If they got just one more drug partnership and bringing in revenue this will sky rocket.

New deal will be announced tomorrow is my guess.

Vyleesi was just registered under Palatin Technologies in EU.

I will preface this by saying, I'm not the biggest Spana because of the warrants.

However, he did get over 570M in deals for bremelanotide alone. They did what they had to do to push a drug through several Phase I-III studies.

Looking back yeah, those warrants created a massive float. However, I think once they get the LATAM, Europe, and Australia/New Zealand deals for Bremelanotide we'll see $4-$5 range easily. This company has a billion market cap written all over it, *if* going forward they play their cards right and don't tap the capital markets.

PL-3994/the rest of the pipeline will be costly. However, compare to bremelanotide each drug is "easier" to study with indications that are quantifiable and measurable, unlike HSDD. So hopefully the cash-on-hand the have will suffice until they hit other milestones or royalties kick in. I see no reason, this company shouldn't hit $4-$5 in 2-3 years.

Any thoughts over here on why Palatin ( $PTN ) removed all references of Rekynda from their website? Simple name change or rebranding or Bremelanotide?


Only one result is now found using their search bar: http://www.palatin.com/?s=rekynda

The latest corporate presentation does not mention rekynda.

Shhhhhhhh! Don't tell anyone :)

Yes, BREM was originally tested in men, in a nasal spray form. However, in Phase 3, there were issues with blood pressure. (A joke IMO). But, now, they are obviously testing in women for HSDD. If that gets approved, BREM could be prescribed "off label" for men, to treat ED.

It's also being studied in Australia to treat Autism in men.

Here is my running list on PTN DD: https://www.reddit.com/r/biotech_stocks/comments/4egkoz/stock_ticket_ptn_anyone_watching_or_own_this_stock/

Mike

I believe there is already a partner or partners, already in place and they are under NDA and waiting for data to be released. Based on those results, the partnership moves forward, etc.

I wish I knew this answer as well. They do this all the time.

I would really have a smidge more confidence, if Steve or Carl would buy on the open market. I do think though, they have a ton of exposure already through their company share program. But, still, it would be nice to see them buy some common shares to boost shareholder confidence.

I really agree with you, these deals do not happen over night or weeks, or days. They probably take a few months to iron out. So yeah, they most likely have a partnership(s) lined up, depending on the data read out.

Plus, the latest corporate presentation, mentions a Phase 3 trial commencing in the EU (subject to funding). To me, that shows they are confidence they will get funding.

Lastly, there wasn't one hint of fear in that conference call. They seemed very excited.

"So there is no question the data that comes out late third quarter is going to be the primary dri[v]er of those collaboration chats but we are not going to be starting the process at an early we're at definitely an advanced stages of discussions and due diligence with a number of potential collaboration partners."

Also, why would folks leave their company to go work at Palatin unless they were sure that Palatin has a future? (Libby Keating and they hired a new Project Manager). :)

September should be fun.

Here is a good running list of DD/reasons to invest in $PTN

https://www.reddit.com/r/biotech_stocks/comments/4egkoz/stock_ticket_ptn_anyone_watching_or_own_this_stock/

Any link to this quote? I'd love to hear/read more about this...

Any link to this quote? I'd love to hear/read more about this...

Heh, sorry to hear that.

that sucks...those GOIG days are long gone.

Ikes e-mail

Ike H Sutton
CEO and Director at TARSIER Ltd. Stock Symbol TAER

Isutton@tarsierltd.com

I agree, this could be a potential game changer for Palatin to have a drug with multiple use cases, in their portfolio.

Any revenue that was generated was from the Gedeon Richter partnership. They hit a few milestones, but then terminated the license agreement.

I'm curious, if Palatin is at all involved with trial by the University of Sydney.

I wrote the University, to see if they could share who might be sponsoring the trials but the school is closed currently (got an out of office email reply).

Either way, if they run a successful trial in Australia, for treating Autism with Bremelanotide, that would be pure gold for Bremelanotide in the US for Palatin. That would certainly open up additional partnership opportunities.

Bremelanotide to treat Austism in males, in Australia?

http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12615001059550

This is very interesting, as Palatin owns the world rights to this drug.

Bremelanotide, is far superior, compared to Addyi. Now, we have to hope they can hold on and not have to do a reverse split, and filter through the "Addyi isn't selling" noise, to get a good deal.

In the past, they have had offers for 250M for Bremelanotide partnership with King Pharmaceuticals. However, that was way before there were regulatory hurdles cleared by another company (Sprout). After this partnership news, in 2004-2006, the stock was trading at roughly, $3 (later there was a 1:10 R/S).

http://finance.yahoo.com/q/hp?s=PTN&a=00&b=15&c=2006&d=11&e=24&f=2006&g=d

http://web.archive.org/web/20060215224758/http://www.palatin.com/strategicalliances/overview.asp

If they can get a partnership, for 500M this could, fly to $4-5 / share easily. Anything above that, would be....well...gravy, with stuffing, turkey, and mashed potatoes.

An old web archive of PTN and their partnership with King.

http://web.archive.org/web/20060215224758/http://www.palatin.com/strategicalliances/overview.asp

The old, value for Bremelanotide from King was 250 Million Dollars.

With all of the regulatory uncertainties out of the way, now that Sprout has approva. This 250M figure, now has to be increased.

Yea, this stock action, is not making me...well...

Video - Best info on PTN

ZZZZZZZZZZZZZZZ

One day $PTN will wake up!

Palatin had mentioned something about the data, from the US trails, could be used in the EU (but I'm sure if that is allowed or not). I think the only way they go the EU route, is if they have a big enough partner to help foot the bill. It sounds like, Gedeon backed out due to the cost associated with the trials in the EU.

One of my assumptions/conspiracies on the Gedeon thing...why they divorced Palatin:
The thing that makes me pause…I was/am under the impression that the cost of trials and the length of trials over there in the EU are, much less costly and shorter in duration then over here in the US. So, let's hope Gedeon didn't find anything negative about the BMT drug in their research.
I'm curious if the breakup is Gedeon just cutting their loss at 12 million, which saved them money, in potential legal fees and lawsuits, etc? Perhaps they know a bit more about the drug. Hopefully, Palatin, is truthful when they say the divorce has nothing to do with BMT or any risk associated with the drug.

LONG $PTN (a tad nervous with Gedeon backing out)

Why Gedeon Walked away from $PTN:

I agree. A partnership brings validity to the company, the drug itself and the possibility of an FDA approval.

A buyout, would be the ideal situation. I think the odds of that happening are high. The CEO has said, that basically someone will buy Sprouts drug once approved (that happened) and that someone will buy Bremelanotide when it is approved (is this happening right now behind closed doors?)


Quote:
I think the main question is really the regulatory uncertainty, and that has been changing. And so I think as the regulatory uncertainty hopefully gets clarified coming out of the June 4 meeting, and then I guess, a little later in the year, should the panel recommend approval, hopefully that drug getting approved, I think that really helps to remove one of the remaining obstacles that we see to finalizing a substantial transaction for bremelanotide.
There are only two of us in the marketplace, I mean there is flibanserin and there's bremelanotide, so there are lot of companies that sell into the OB/GYN space, so if one gets one, somebody is going to need another one. So I think we'd be well-positioned.

Interesting, I dont see this announced on the $PTN website.

Conference Call Transcript that is interesting:

From a past Palatin Conference Call I was just reading through ---

according to Yahoo:

Shares Short (as of Jul 31, 2015)3: 1.94M

http://finance.yahoo.com/q/ks?s=PTN

Not sure if that's what you're looking for as far as shares shorted of $PTN.

I agree 100%...it "should be" a win-win situation if Sprout is approved or denied for $PTN

Sounds like we're in a good spot, come August 18th. Fingers are crossed...

20k shares, locked and loaded.

Committee approval rate - link

www.njbiz.com/article/20150615/NJBIZ01/306159990/palatin-eager-to-benefit-from-landmark-fda-ruling


Seton Hall University School of Law professor Jordan Paradise agreed.

“If the committee green-lights something, the FDA commissioner can still say no, but that happens almost never,” she said. “A green-light from committee means it’s basically in the bag, but you never know.”

Historically, Paradise said 74 percent of drugs approved by the committee are granted final approval.

And with a history of controversy around female HSDD drugs, Paradise said it was interesting to see a company directly addressing the issues.

I asked the same question a few post down. There is a link somewhere on here, or stock twits that suggest, its around 80% ish....I can't seem to find it at the moment.

So come August, there are two obvious possibilities:

Sprout gets FDA approval, PTN sky rockets to $1.5-2

Sprout gets FDA denial, PTN falls to $.25-$.50

"Advisory committees provide FDA with independent opinions and recommendations from outside experts on applications to market new drugs, and on FDA policies. The marketing applications include data to show the safety and effectiveness of human drugs. The outside experts receive summary information about the applications and copies of FDA's review of the application documents. Based on this information, advisory committees may recommend approval or disapproval of a drug's marketing application. FDA generally follows an advisory committee's recommendation, but is not bound to do so. "


I've read a statistic, that suggested that the FDA has followed the advisory committee roughly 84% of the time. I can't find the link though, but that's decent odds for Sprout and that news should impact the value of PTN's stock. Does anyone have any data around FDA approval and the advisory committee's recommendations?


I do find this quote interesting:


www.fda.gov/downloads/drugs/newsevents/ucm423111.pdf

I believe, the phase 3 news will happen closer to mid/end of 2016.

Yeah, I went back and re-read the filings. You're correct, those were free shares.

But, hopefully they want those shares to be valued at $10 minimum ;)

I agree! Just yesterday I purchased a few more shares. And this news comes out:

CEO of Palatin buying shares:

insert-text-here

I like that insiders are purchasing!

I've been following and have owned this stock for a while. I've always missed the swing trade. But, typically this stock spikes up around $1.5 and then crashes to around .90 range and sits there (plus or minus a few pennies).

I really like buying as much as I can afford to, under $1. I plan to accumulate this entire year, when I see a nice dip in price. It could bring an early christmas if the buyout rumors start!

Known fact is, Palatin is looking for a U.S. partner to help continue the development and commercialization of BMT (Bremelanotide). If a name like Pfizer gets in the mix, I'd be very happy.

All of the previous meetings, PTN management has stated they were looking to have their U.S. partnership locked up this year. Gideon Richer, signed as their European partner not too long ago and even paid out a milestone payment of ~3 million USD.

So the potential is there. I like the linkage to Pfizer and Palatin. Hopefully, with the FDA approving a female sexual drug, this can help accelerate PTN finding and inking a U.S. partner.


However, its not JOHN K.A. PRENDERGAST that is linked to Pfizer, its Angela Rossetti:

ANGELA ROSSETTI
Director

Ms. Rossetti has been a director since June 2013. From 2009 through January 2012, she was a vice president at Pfizer Inc., where she led a global commercial medicine team for a smoking cessation franchise. She was an assistant vice president at Wyeth, managing a global hemophilia franchise from 2007 until 2009, when Wyeth was acquired by Pfizer. From 2005 to 2006 she was president of Ogilvy Healthworld, an advertising business in the pharmaceutical and biotechnology sectors. Previously she worked in a variety of increasingly responsible positions in communications, marketing and venture capital/investment banking.

insert-text-here

CRANBURY, N.J., June 4, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) - Today's FDA Advisory Committee's recommendation for the approval of flibanserin is an important step forward in women's health, as the decision addresses the important need for the women living with hypoactive sexual desire disorder, or HSDD, to have an approved treatment option.

A stock owner, would know that Palatin is not developing Flibanserin. Palatin, is developing a drug called Bremelanotide.

I don't doubt, some folks may have been a tad confused. But, I think most understood the difference. In fact, the Press release later states:

Palatin Technologies is excited to continue the development of bremelanotide, a first-in-class, as needed, melanocortin-4 receptor agonist being studied for the treatment of HSDD in pre-menopausal women. Bremelanotide has a novel mechanism that activates endogenous pathways in the brain involved in creating a sexual response. It is unique because bremelanotide is an as-needed (not chronic), centrally-mediated medication. Studies have shown that it starts working within 30 to 60 minutes of administration and remains effective for approximately eight hours, providing women with greater control and flexibility in their treatment.